[{"NetIncomeLossConverted_1_Q3_USD":-27221000.0,"NetCashProvidedByUsedInOperatingActivitiesConverted_3_Q3_USD":-75030000.0,"CommonStockSharesOutstanding_0_Q3_shares":66324753.0,"StockholdersEquity_0_Q3_USD":505070000.0,"EarningsPerShareBasic_1_Q3_USD":-0.42,"EarningsPerShareBasic_3_Q3_USD":-1.49,"RevenuesConverted_1_Q3_USD":12661000.0,"RevenuesConverted_3_Q3_USD":34232000.0,"Assets_0_Q3_USD":595070000.0,"CommonStockSharesConverted_0_Q3_shares":66324753.0,"NetIncomeLossConverted_3_Q3_USD":-76174000.0,"Ticker":"RVMD","CIK":"1628171","name":"REVOLUTION MEDICINES, INC.","OfficialName":"Revolution Medicines Inc. Common Stock","form":"10-Q","period":"20200930","fy":"2020.0","fp":"Q3","qtrs":"1","uom":"USD","footnote":"nan","Market Cap":"1775342076.0","Country":"United States","Sector":"Consumer Durables","Industry":"Specialty Chemicals","Market":"NASDAQ","SP500":"nan","filed":"20201112"}]